Volume 5.04 | Feb 3

Cancer Stem Cell News 5.04 February 3, 2016
Cancer Stem Cell News
     In this issue: Publications | Reviews | Industry News | Policy News | Events | Jobs
Cell Therapy News on Facebook  CSCN on Twitter
 
TOP STORY
Downregulation of TLX Induces TET3 Expression and Inhibits Glioblastoma Stem Cell Self-Renewal and Tumorigenesis
Researchers identified the regulatory cascade of the nuclear receptor TLX and the DNA hydroxylase Ten eleven translocation 3 (TET3) as a target for human glioblastoma stem cells. [Nat Commun] Full Article
Learn more about T cell activation and expansion with ImmunoCult™
 
PUBLICATIONS (Ranked by impact factor of the journal)
Combination of Drug-Conjugated SWCNTs Nanocarriers for Efficient Therapy of Cancer Stem Cells in a Breast Cancer Animal Model
The researchers evaluated the potential therapeutic efficacy of combining Paclitaxel and Salinomycin drugs actively targeted to both breast cancer and cancer stem cells in a xenograft murine model after conjugation with biocompatible CD44 antibodies conjugated SWCNTs via hydrazone linker allowing pH-responsive release mechanism near the acidic tumor microenvironment. [J Control Release] Abstract

Core Pathway Mutations Induce De-Differentiation of Murine Astrocytes into Glioblastoma Stem Cells that Are Sensitive to Radiation but Resistant to Temozolomide
To model genetic alterations in human glioblastomas core signaling pathways, researchers induced Rb knockout, Kras activation, and Pten deletion mutations in cortical murine astrocytes. [Neuro Oncol] Abstract

A Synthetic Polymer Scaffold Reveals the Self-Maintenance Strategies of Rat Glioma Stem Cells by Organization of the Advantageous Niche
The authors used polymer microarrays for the rapid and efficient identification of glioma cancer stem cells niche mimicries and identified a urethane-based synthetic polymer, upon which two groups of niche components, namely extracellular matrices and iron were revealed. [Stem Cells] Abstract

Ki-67 Is Required for Maintenance of Cancer Stem Cells but Not Cell Proliferation
Researchers demonstrated that genetic disruption of Ki-67 in human epithelial breast and colon cancer cells depletes the cancer stem cell niche. Ki-67 null cells had a proliferative disadvantage compared to wildtype controls in colony formation assays and displayed increased sensitivity to various chemotherapies. [Oncotarget] Full Article 

IL-32θ Inhibits Stemness and Epithelial-Mesenchymal Transition of Cancer Stem Cells via the STAT3 Pathway in Colon Cancer
Ectopic expression of interleukin (IL)-32θ attenuated invasion, migration in vitro and in vivo tumorigenicity of colon cancer cells. IL-32θ inhibited epithelial-mesenchymal transition, resulting in the suppression of their migratory and invasive capabilities of HT29 colon cancer cells. [Oncotarget] Full Article

Development of Liposomal Formulation for Delivering Anticancer Drug to Breast Cancer Stem Cell-Like Cells and Its Pharmacokinetics in an Animal Model
The objective of the present study was to develop a liposomal formulation for delivering anticancer drug to breast cancer stem cell-like cells, ANV-1, and evaluate its pharmacokinetics in an animal model. [Mol Pharm] Abstract

Investigating the Radioresistant Properties of Lung Cancer Stem Cells in the Context of the Tumor Microenvironment
Investigators utilized a three-dimensional non-small cell lung cancer model, which had characteristics of the tumor microenvironment and tumor cell heterogeneity, to elucidate the multifactorial nature of radioresistance in tumors. [Radiat Res] Abstract

A1E Reduces Stemness and Self-Renewal in HPV 16-Positive Cervical Cancer Stem Cells
The authors investigated whether A1E can regulate epithelial-to-mesenchymal transition (EMT), cancer stem cells self-renewal, and stemness-related gene expression in cervical cancer cells. Down regulation of cell migration, cell invasion, and EMT was observed in A1E-treated SiHa cells. [BMC Complement Altern Med] Full Article

Mitochondrial Oligomers Boost Glycolysis in Cancer Stem Cells to Facilitate Blebbishield-Mediated Transformation after Apoptosis
Scientists demonstrated that N-Myc and VEGFR2 control transformation from blebbishields, during which oligomers of K-Ras, p27, BAD, Bax, and Bak boost glycolysis to avoid secondary necrosis. [Cell Death Discov] Full Article

Request your Free Wallchart on Naive and Primed Stem Cell States
 
REVIEWS
Touch and Go -Nuclear Proteolysis in the Regulation of Metabolic Genes and Cancer
The authors highlight recent findings in the emerging field of nuclear proteolysis and outline novel paradigms for cancer treatment, with an emphasis on multiple myeloma. [FEBS Lett] Full Article

Visit our reviews page to see a complete list of reviews in the cancer stem cell research field.
 
INDUSTRY NEWS
Morphotek Announces Collaboration with Mayo Clinic to Apply its Folate Receptor Alpha Diagnostic Assays in a Phase II Clinical Trial in Triple-Negative Breast Cancer
Morphotek, Inc. announced that it is collaborating with researchers Keith L. Knutson, Ph.D. in the Department of Immunology and Edith A. Perez, M.D. in the Department of Hematology and Oncology at Mayo Clinic in Jacksonville, Florida in a clinical study in patients with folate receptor alpha positive, triple-negative breast cancer. [Morphotek, Inc.] Press Release

NEUMANN Diagnostics’ Automated Cervical Cancer Test Achieves Exceptional Accuracy
Molecular assays developer NEUMANN Diagnostics Ltd. unveiled its CONFIDENCE™ molecular test portfolio setting a new standard in cervical cancer screening. The tests demonstrated superior accuracy achieving very high sensitivity without compromising on specificity. [Neumann Diagnostics Ltd.] Press Release

TapImmune Granted Fast Track Designation by U.S. Food & Drug Administration for its Lead Vaccine TPIV 200 in the Treatment of Ovarian Cancer
TapImmune, Inc. announced that the United States Food & Drug Administration has granted Fast Track Designation for its cancer vaccine TPIV 200 in the treatment of ovarian cancer. [TapImmune] Press Release

From our sponsor:
Webinar: Brent Reynolds on the identification and characterization of neural stem cells.
Watch now.
 
POLICY NEWS
National Institutes of Health (United States)

Food and Drug Administration (United States)

Center for Biologics Evaluation and Research (United States)

European Medicines Agency (European Union)

Medicines and Healthcare Products Regulatory Agency (United Kingdom)

Therapeutic Goods Administration (Australia)
 
EVENTS
NEW 3rd Immunotherapy of Cancer Conference (ITOC)
March 21-23, 2016
Munich, Germany

Visit our events page to see a complete list of events in the cancer stem cell community.
 
JOB OPPORTUNITIES
NEW Faculty Position – Radioimmunotherapy (Fred Hutchinson Cancer Research Center)

NEW Director Manufacturing – Cell and Gene Therapy (Fred Hutchinson Cancer Research Center)

NEW Lab Technician – Hematopoietic Stem Cell Biology (Fred Hutchinson Cancer Research Center)

NEW Research Assistant – Breast Cancer Biology (National University of Ireland Galway)

Post-Doc Fellowships – Integrative Analysis in Prostate and Breast Cancer (Baylor College of Medicine)

Research Scientist – Hematopoietic Stem Cell Transplantation (University of Chicago)

Staff Scientist – Cell Therapy Process Development (Fred Hutchinson Cancer Research Center)

Post-Doc Fellowship – Bioinformatics RNA Biology and Cancer (German Cancer Research Center)

Post-Doc Fellowship – Genetics and Genomics of Stem Cells (Albert Einstein College of Medicine of Yeshiva University)

Tenure Track Professorship – Tumor Biology and Signal Transduction (University Medical Center Gottingen)

Professor – Cancer Immunotherapy (Stanford Cancer Institute)

Postdoctoral Fellow – Cell and Molecular Biology of Leukemia (Virginia Commonwealth University)

Postdoctoral Fellow – Cancer Stem Cell Biology (Cleveland Clinic)


Recruit Top Talent: Reach more than 60,000 potential candidates by posting your organization’s career opportunities on the Connexon Creative Job Board at no cost.
 

Have we missed an important article or publication in Cancer Stem Cell News? Click here to submit!

Comments or suggestions? Submit your feedback here
Learn more about Cancer Stem Cell News: Archives | Events | Contact Us